EurekaMag.com logo
+ Translate

Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action


, : Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action. Arzneimittel-Forschung 37(1): 14-16

In experiments on 6 mongrel dogs the electrophysiologic effects of the new antiarrhythmic compound (.+-.)-6,7,8,9-tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5H-dibenz[d,f]azonin-1-ol (asocainol) were examined in the non-ischemic heart. The PR interval increased significantly following doses of 5 mg/kg caused by a conduction delay in the His-Purkinje system. At high doses (10 mg/kg) the QRS duration was also prolonged. Atrial and ventricular effective refractory periods were only slightly increased. Asocainol significantly increased the atrial fibrillation threshold, whereas the ventricular fibrillation threshold was not altered. Hemodynamics were not changed except for a slight increase in heart rate after 10 mg/kg asocainol. Thus asocainol predominantly exhibited class Ia antiarrhythmic properties, whereas calcium antagonistic actions could not be established in this intact dog heart model.

(PDF 0-2 workdays service)

Accession: 005349288

PMID: 3566851

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Koerner, J.E.; Dage, R.C., 1990: Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs. MDL 11,939 (.alpha.-phenyl-1-[2-phenylethyl]-4-piperidine-methanol) is a new class III antiarrhythmic agent that was evaluated for antiarrhythmic activity in anesthetized dogs. Intravenous (i.v.) administration of MDL 11,939 (1, 3, and 10 mg/kg) i...

Katoh H.; Nomoto K.; Sawada K.; Shoji T., 1988: Electrophysiologic antiarrhythmic and hemodynamic effects of e 4031 a novel class iii antiarrhythmic agent in intact and infarcted dogs. European Heart Journal 9(ABSTR SUPPL 1): 232

Colatsky T.J.; Follmer C.H.; Bird L.B., 1989: Cardiac electrophysiologic effects of wy 48986 a novel class iii antiarrhythmic agent. Journal of Molecular & Cellular Cardiology 21(SUPPL 2): S20

Atarashi, H.; Iida, K.; Kou, M.; Hirayama, Y.; Gotoh, M.; Ino, T.; Katoh, T.; Hayakawa, H., 1988: Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent. Electrophysiologic effects of cibenzoline (1.4 mg/kg/3 min), a new class I antiarrhythmic agent, were investigated in 9 patients with PSVT including WPW syndrome and 5 patients with ventricular tachycardia. Cibenzoline significantly shortened sinu...

Isomoto, S.; Shimizu, A.; Konoe, A.; Kaibara, M.; Centurion, O.A.; Fukatani, M.; Yano, K., 1993: Electrophysiologic effects of E-4031, a new class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. American Journal of Cardiology 71(16): 1464-1467

Sager P.; Antimisiaris M.; Neiditch T.; Stewart C.; Pruitt C.; Singh B., 1991: Frequency dependent electrophysiologic effects of sematilide a pure class iii antiarrhythmic agent. Circulation 84(4 SUPPL 2): II350

Winslow, E.; Martorana, M.; Bell, P., 1989: Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. The in vitro electrophysiologic effects of a new class I steroidal antiarrhythmic agent, Org 7797 (2-10 microM) were evaluated in porcine ventricular and Purkinje tissue using conventional microelectrode techniques. Org 7797-induced decreases in V...

Naitoh, N.; Taneda, K.; Tagawa, M.; Furushima, H.; Yamaura, M.; Aizawa, Y., 1998: Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle. The effects of intravenous MS-551, a new class III antiarrhythmic drug, on atrium and ventricle were evaluated in 6 patients with ventricular tachyarrhythmias (4 males and 2 females; mean age 45 +/- 21 years) in an electrophysiologic study. Two pa...

Golitsyn, S.; Maikov, E.; Krutanov, I.; Bakalov, S.; Ruda, M.; Rosenshtrauh, L.; Chazov, E., 1996: Electrophysiologic and antiarrhythmic effects of the nibentan, a new class III agent, in patients with paroxysmal tachyarrhythmias. European Heart Journal 17(ABSTR SUPPL ): 389

Argentieri, T.M.; Troy, H.H.; Carroll, M.S.; Doroshuk, C.M.; Sullivan, M.E., 1993: Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties. CK-3579 (N-(4-(2-hydroxy-3-((2-(4-(1H-inidazol-1-yl)phenoxy)ethyl)amino)propoxy)phenyl)-methanesulfonamide, HCL-(RS)), is a new class III antiarrhythmic agent with beta-adrenoceptor blocking properties shown to be effective in preventing ventricul...